{"id":2667,"date":"2021-10-18T08:38:12","date_gmt":"2021-10-18T06:38:12","guid":{"rendered":"https:\/\/www.socesfar.es\/revista\/revista-1\/"},"modified":"2021-10-18T08:38:13","modified_gmt":"2021-10-18T06:38:13","slug":"revista-1","status":"publish","type":"revista","link":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/","title":{"rendered":"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021"},"content":{"rendered":"\n<p><strong>Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica<\/strong><br\/><strong><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/AFTV19N12021-WEB.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021<\/a><\/strong><\/p>\n\n<h4 class=\"wp-block-heading\"><strong>\u00cdndice<\/strong><\/h4>\n\n<ul class=\"wp-block-list\"><li><strong>Editorial del Presidente.<\/strong><a href=\"https:\/\/www.socesfar.es\/images\/joomlart\/revista\/2021\/19-1\/AFTV19N1-01%20Edit%20presidente.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"> <\/a><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-01-Edit-presidente.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">La investigaci\u00f3n cooperativa<\/a><\/li><li><strong>Editorial del Director.<\/strong><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-02-Edit-director.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Ciencia jubilar: receptor P2X7<\/a><\/li><li><strong>Editorial invitado.<\/strong><ul><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03A-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">40 a\u00f1os no son nada&#8230; La Sociedad de Farmacolog\u00eda de Chile, a prop\u00f3sito de una pandemia<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03B-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Geoffrey Burnstock 1929-2020<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03C-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">La epidemia de adicci\u00f3n a opioides en los Estados Unidos<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03D-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">PowerPoint: una herramienta \u00fatil de manejo delicado<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03E-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">De los canales i\u00f3nicos al ojo seco. Una peque\u00f1a historia de emprendimiento con final feliz<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-03F-Editorial-invitado.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Asociaci\u00f3n Argentina de Farmacolog\u00eda Experimental: legado, presente y futuro<\/a><\/li><\/ul><\/li><li><strong>Investigaci\u00f3n traslacional.<\/strong><a href=\"https:\/\/www.socesfar.es\/images\/joomlart\/revista\/2021\/19-1\/AFTV19N1-05%20Traslacion.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"> <\/a><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-05-Traslacion.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y su aplicaci\u00f3n cl\u00ednica<\/a><\/li><li><strong>Revisiones en Farmacoterapia<\/strong><ul><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-06A-Revisiones-en-farmacoterapia.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lurasidona, estrenando antipsic\u00f3tico en adolescentes<\/a><\/li><\/ul><\/li><li><strong>Casos farmacoter\u00e1picos. <\/strong><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-07-Casos-farmacote.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Aplicaci\u00f3n de la farmacogen\u00e9tica en Psiquiatr\u00eda: depresi\u00f3n resistente a tratamiento<\/a><\/li><li><strong>Cultura y F\u00e1rmacos<\/strong><ul><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-10-CYF.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">&#8220;Refranes y otras paremias&#8221;<\/a><\/li><li><a href=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/09\/AFTV19N1-10B-CYF.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Recetario Po\u00e9tico<\/a><\/li><\/ul><\/li><li><strong>Normas para los autores<\/strong><\/li><\/ul>\n<p><\/p>\n","protected":false},"featured_media":0,"template":"","categoria_revista":[66],"class_list":["post-2667","revista","type-revista","status-publish","hentry","categoria_revista-2021-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda<\/title>\n<meta name=\"description\" content=\"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda\" \/>\n<meta property=\"og:description\" content=\"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Sociedad Espa\u00f1ola de Farmacolog\u00eda\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-18T06:38:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/AFTV19N12021-WEB.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Socesfar\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/\",\"url\":\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/\",\"name\":\"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda\",\"isPartOf\":{\"@id\":\"https:\/\/www.socesfar.es\/en\/#website\"},\"datePublished\":\"2021-10-18T06:38:12+00:00\",\"dateModified\":\"2021-10-18T06:38:13+00:00\",\"description\":\"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.socesfar.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revistas\",\"item\":\"https:\/\/www.socesfar.es\/en\/revistas\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.socesfar.es\/en\/#website\",\"url\":\"https:\/\/www.socesfar.es\/en\/\",\"name\":\"Sociedad Espa\u00f1ola de Farmacolog\u00eda\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.socesfar.es\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.socesfar.es\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.socesfar.es\/en\/#organization\",\"name\":\"Sociedad Espa\u00f1ola de Farmacolog\u00eda\",\"url\":\"https:\/\/www.socesfar.es\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.socesfar.es\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/logo-socesfar-02.png\",\"contentUrl\":\"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/logo-socesfar-02.png\",\"width\":383,\"height\":63,\"caption\":\"Sociedad Espa\u00f1ola de Farmacolog\u00eda\"},\"image\":{\"@id\":\"https:\/\/www.socesfar.es\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/Socesfar\",\"https:\/\/www.linkedin.com\/company\/socesfar\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda","description":"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/","og_locale":"en_US","og_type":"article","og_title":"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda","og_description":"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.","og_url":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/","og_site_name":"Sociedad Espa\u00f1ola de Farmacolog\u00eda","article_modified_time":"2021-10-18T06:38:13+00:00","og_image":[{"url":"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/AFTV19N12021-WEB.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@Socesfar","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/","url":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/","name":"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021 - Sociedad Espa\u00f1ola de Farmacolog\u00eda","isPartOf":{"@id":"https:\/\/www.socesfar.es\/en\/#website"},"datePublished":"2021-10-18T06:38:12+00:00","dateModified":"2021-10-18T06:38:13+00:00","description":"Da\u00f1o cerebral y neurodegeneraci\u00f3n: Papel protector de la melatonina y aplicaci\u00f3n cl\u00ednica. Actualidad en Farmacolog\u00eda y Terap\u00e9utica.","breadcrumb":{"@id":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.socesfar.es\/en\/revista\/revista-1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.socesfar.es\/en\/revista\/revista-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.socesfar.es\/en\/"},{"@type":"ListItem","position":2,"name":"Revistas","item":"https:\/\/www.socesfar.es\/en\/revistas\/"},{"@type":"ListItem","position":3,"name":"Actualidad en Farmacolog\u00eda y Terap\u00e9utica. Vol. 19, n\u00ba 1, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.socesfar.es\/en\/#website","url":"https:\/\/www.socesfar.es\/en\/","name":"Sociedad Espa\u00f1ola de Farmacolog\u00eda","description":"","publisher":{"@id":"https:\/\/www.socesfar.es\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.socesfar.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.socesfar.es\/en\/#organization","name":"Sociedad Espa\u00f1ola de Farmacolog\u00eda","url":"https:\/\/www.socesfar.es\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.socesfar.es\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/logo-socesfar-02.png","contentUrl":"https:\/\/www.socesfar.es\/wp-content\/uploads\/2021\/07\/logo-socesfar-02.png","width":383,"height":63,"caption":"Sociedad Espa\u00f1ola de Farmacolog\u00eda"},"image":{"@id":"https:\/\/www.socesfar.es\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Socesfar","https:\/\/www.linkedin.com\/company\/socesfar\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/revista\/2667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/revista"}],"about":[{"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/types\/revista"}],"version-history":[{"count":1,"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/revista\/2667\/revisions"}],"predecessor-version":[{"id":2668,"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/revista\/2667\/revisions\/2668"}],"wp:attachment":[{"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/media?parent=2667"}],"wp:term":[{"taxonomy":"categoria_revista","embeddable":true,"href":"https:\/\/www.socesfar.es\/en\/wp-json\/wp\/v2\/categoria_revista?post=2667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}